Morgan Stanley downgraded Prelude Therapeutics to Underweight from Equal Weight with a price target of $4, down from $10. While the firm still likes Prelude’s approach for its SMARCA2 and CDK9 programs, the firm thinks proof-of-concept data in mid-2024 are needed for both and sees better risk-adjusted opportunities elsewhere in the firm’s pharma coverage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PRLD:
- Prelude Therapeutics Announces $25 Million Private Placement
- Prelude Therapeutics price target lowered to $5 from $6 at H.C. Wainwright
- Prelude Therapeutics price target lowered to $3 from $5 at Barclays
- Prelude Therapeutics updates pipeline ‘s clinical progress, prioritization
- Prelude, AbCellera team on precision antibody drug conjugates in oncology